This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: The efficacy and safety of oral pharmacokinetically enhanced amoxycillin–clavulanate 2000/125 mg, twice daily, versus oral amoxycillin–clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults, International Journal of Antimicrobial Agents, August 2002, Elsevier,
DOI: 10.1016/s0924-8579(02)00126-7.
You can read the full text:
The following have contributed to this page
